Romanians last year spent four times less than West Europeans on drugs per person.
The Romanian pharmaceutical market will witness average annual growth of 13.3% by 2010, according to estimates by KBC Securities analysts.
They expect drug consumption per capita in Romania to rapidly get close to the average of Central and Eastern Europe and subsequently to that of Western Europe.
Romanians spent 92 dollars on average on drugs per person last year, compared with an average of 135 dollars in Central and East-European states and of 374 dollars in Western Europe.
The domestic pharmaceutical market has witnessed rapid expansion in recent years, increasing by 18% in 2005 and by 20% in 2006, to 5.4bn RON (1.95bn euros).
The expansion was driven by the simplification of drug registration procedures and by the rising GDP per capita, shows KBC's survey.
KBC analysts expect the Romanian pharmaceutical sector to continue to grow faster than the overall economy.
Growth will be spurred by the development of the private medical services sector, the rising population incomes and life expectancy, as well as by the changing population behaviour, with people to focus more on prevention rather than treatment.
KBC estimates the over-the-counter drug market will rise faster than that of drugs released on the basis of a prescription, to witness average annual growth by 15.3% by 2013.
KBC considers pharmaceutical market rules in Romania are as strict as those in other states of Central and Eastern Europe, which is limiting downside risks.
Analysts do not rule out the possibility of the market witnessing bigger increases than they estimate as the Health Ministry changes drug calculation methods, though saying that it may not happen because of the unstable political environment.
The Health ministry plans to change the way drug prices are calculated in a bid to bring the price of drugs released on the basis of a prescription to the lowest levels of the most competitive EU states in terms of price policy.
Authorities also plan to modify drug prices annually or any time macroeconomic conditions make this necessary, instead of on a quarterly basis as it happens at present. At the same time, authorities ask for discounts at the moment generic drugs are introduced on the market.
Drug demand is expected to increase as rising funds will be earmarked for the health care sector.
KBC considers the current gap between Romania's economic growth and that of richer neighbours part of the EU is set to narrow as part of the convergence process. This is expected to have a major influence over the health sector.
Pentru alte știri, analize, articole și informații din business în timp real urmărește Ziarul Financiar pe WhatsApp Channels
